A dependence between the percentage of CD14+CD16−SLAN− classical monocytes and the clinical stage of CLL according to Rai was noted; the percentage of CD14+CD16−SLAN− monocytes increased with disease progression, the lowest value was noted in the low-risk group (median (IQR) 81.14 (74.48–86.88)%). This evidence concerns the gene CD14 and B-cell chronic lymphocytic leukemia.